Tumor Landscapes: β-Catenin Drives Immune Desertification.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 30837277.
- Also identified by DOI 10.1158/1078-0432.CCR-19-0188.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Immune checkpoint blockade therapy requires a preestablished activated immune landscape. Understanding tumor-intrinsic mechanisms that lead to T-cell desertification is key to resensitizing them to such therapies. The WNT/β-catenin tumor-intrinsic signaling is emerging as an immune exclusion pathway that holds high promise to counteract resistance to immunotherapy.<i>See related article by Luke et al., p. 3074</i>.
Medical subject headings
- Neoplasms
- beta Catenin